-
Personalized medicine: challenges in biomarker-related clinical trial design
Pei He
Clinical Trail Methodology: Clinical Investigation
-
Personalized medicine: challenges in biomarker-related clinical trial design
Pei He
Clinical Trail Methodology: Clinical Investigation
-
Personalized medicine: challenges in biomarker-related clinical trial design
Pei He
Clinical Trail Methodology: Clinical Investigation
-
Personalized medicine: challenges in biomarker-related clinical trial design
Pei He
Clinical Trail Methodology: Clinical Investigation
-
Personalized medicine: challenges in biomarker-related clinical trial design
Pei He
Clinical Trail Methodology: Clinical Investigation
-
Personalized medicine: challenges in biomarker-related clinical trial design
Pei He
Clinical Trail Methodology: Clinical Investigation
-
Personalized medicine: challenges in biomarker-related clinical trial design
Pei He
Clinical Trail Methodology: Clinical Investigation
-
Personalized medicine: challenges in biomarker-related clinical trial design
Pei He
Clinical Trail Methodology: Clinical Investigation
-
Data fraud in clinical trials
Stephen L George, & Marc Buyse
Clinical Trail Perspective: Clinical Investigation
-
Data fraud in clinical trials
Stephen L George, & Marc Buyse
Clinical Trail Perspective: Clinical Investigation
-
Data fraud in clinical trials
Stephen L George, & Marc Buyse
Clinical Trail Perspective: Clinical Investigation
-
Data fraud in clinical trials
Stephen L George, & Marc Buyse
Clinical Trail Perspective: Clinical Investigation
-
Data fraud in clinical trials
Stephen L George, & Marc Buyse
Clinical Trail Perspective: Clinical Investigation
-
Data fraud in clinical trials
Stephen L George, & Marc Buyse
Clinical Trail Perspective: Clinical Investigation
-
Data fraud in clinical trials
Stephen L George, & Marc Buyse
Clinical Trail Perspective: Clinical Investigation
-
Data fraud in clinical trials
Stephen L George, & Marc Buyse
Clinical Trail Perspective: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
The phosphatidyl-inositol 3-kinase/Akt/ mammalian target of rapamycin pathway as a therapeutic target in head and neck cancer
Saad A Khan & Julie E Bauman
Clinical Trail Outcomes: Clinical Investigation
-
The phosphatidyl-inositol 3-kinase/Akt/ mammalian target of rapamycin pathway as a therapeutic target in head and neck cancer
Saad A Khan & Julie E Bauman
Clinical Trail Outcomes: Clinical Investigation
-
The phosphatidyl-inositol 3-kinase/Akt/ mammalian target of rapamycin pathway as a therapeutic target in head and neck cancer
Saad A Khan & Julie E Bauman
Clinical Trail Outcomes: Clinical Investigation
-
The phosphatidyl-inositol 3-kinase/Akt/ mammalian target of rapamycin pathway as a therapeutic target in head and neck cancer
Saad A Khan & Julie E Bauman
Clinical Trail Outcomes: Clinical Investigation
-
The phosphatidyl-inositol 3-kinase/Akt/ mammalian target of rapamycin pathway as a therapeutic target in head and neck cancer
Saad A Khan & Julie E Bauman
Clinical Trail Outcomes: Clinical Investigation
-
The phosphatidyl-inositol 3-kinase/Akt/ mammalian target of rapamycin pathway as a therapeutic target in head and neck cancer
Saad A Khan & Julie E Bauman
Clinical Trail Outcomes: Clinical Investigation
-
The phosphatidyl-inositol 3-kinase/Akt/ mammalian target of rapamycin pathway as a therapeutic target in head and neck cancer
Saad A Khan & Julie E Bauman
Clinical Trail Outcomes: Clinical Investigation
-
The phosphatidyl-inositol 3-kinase/Akt/ mammalian target of rapamycin pathway as a therapeutic target in head and neck cancer
Saad A Khan & Julie E Bauman
Clinical Trail Outcomes: Clinical Investigation
-
Agalsidase alfa for the treatment of fabry disease: a closer look
Shawn E Lipinski, Edina Komlodi-Pasztor & Ozlem Goker-Alpan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Agalsidase alfa for the treatment of fabry disease: a closer look
Shawn E Lipinski, Edina Komlodi-Pasztor & Ozlem Goker-Alpan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Agalsidase alfa for the treatment of fabry disease: a closer look
Shawn E Lipinski, Edina Komlodi-Pasztor & Ozlem Goker-Alpan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Agalsidase alfa for the treatment of fabry disease: a closer look
Shawn E Lipinski, Edina Komlodi-Pasztor & Ozlem Goker-Alpan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Agalsidase alfa for the treatment of fabry disease: a closer look
Shawn E Lipinski, Edina Komlodi-Pasztor & Ozlem Goker-Alpan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Agalsidase alfa for the treatment of fabry disease: a closer look
Shawn E Lipinski, Edina Komlodi-Pasztor & Ozlem Goker-Alpan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Agalsidase alfa for the treatment of fabry disease: a closer look
Shawn E Lipinski, Edina Komlodi-Pasztor & Ozlem Goker-Alpan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Agalsidase alfa for the treatment of fabry disease: a closer look
Shawn E Lipinski, Edina Komlodi-Pasztor & Ozlem Goker-Alpan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
HIV Vaccine Trials Network: activities and achievements of the first decade and beyond
James G Kublin, Cecilia A Morgan, Tracey A Day, Peter B Gilbert, Steve G Self, M Juliana McElrath & Lawrence Corey
Research Update: Clinical Investigation
-
HIV Vaccine Trials Network: activities and achievements of the first decade and beyond
James G Kublin, Cecilia A Morgan, Tracey A Day, Peter B Gilbert, Steve G Self, M Juliana McElrath & Lawrence Corey
Research Update: Clinical Investigation
-
HIV Vaccine Trials Network: activities and achievements of the first decade and beyond
James G Kublin, Cecilia A Morgan, Tracey A Day, Peter B Gilbert, Steve G Self, M Juliana McElrath & Lawrence Corey
Research Update: Clinical Investigation
-
HIV Vaccine Trials Network: activities and achievements of the first decade and beyond
James G Kublin, Cecilia A Morgan, Tracey A Day, Peter B Gilbert, Steve G Self, M Juliana McElrath & Lawrence Corey
Research Update: Clinical Investigation
-
HIV Vaccine Trials Network: activities and achievements of the first decade and beyond
James G Kublin, Cecilia A Morgan, Tracey A Day, Peter B Gilbert, Steve G Self, M Juliana McElrath & Lawrence Corey
Research Update: Clinical Investigation
-
HIV Vaccine Trials Network: activities and achievements of the first decade and beyond
James G Kublin, Cecilia A Morgan, Tracey A Day, Peter B Gilbert, Steve G Self, M Juliana McElrath & Lawrence Corey
Research Update: Clinical Investigation
-
HIV Vaccine Trials Network: activities and achievements of the first decade and beyond
James G Kublin, Cecilia A Morgan, Tracey A Day, Peter B Gilbert, Steve G Self, M Juliana McElrath & Lawrence Corey
Research Update: Clinical Investigation
-
HIV Vaccine Trials Network: activities and achievements of the first decade and beyond
James G Kublin, Cecilia A Morgan, Tracey A Day, Peter B Gilbert, Steve G Self, M Juliana McElrath & Lawrence Corey
Research Update: Clinical Investigation
-
Neuroblastoma drug development: from lab bench to bedside?
Louis Chesler
Interview: Clinical Investigation
-
Neuroblastoma drug development: from lab bench to bedside?
Louis Chesler
Interview: Clinical Investigation
-
Neuroblastoma drug development: from lab bench to bedside?
Louis Chesler
Interview: Clinical Investigation
-
Neuroblastoma drug development: from lab bench to bedside?
Louis Chesler
Interview: Clinical Investigation
-
Neuroblastoma drug development: from lab bench to bedside?
Louis Chesler
Interview: Clinical Investigation
-
Neuroblastoma drug development: from lab bench to bedside?
Louis Chesler
Interview: Clinical Investigation
-
Neuroblastoma drug development: from lab bench to bedside?
Louis Chesler
Interview: Clinical Investigation
-
Neuroblastoma drug development: from lab bench to bedside?
Louis Chesler
Interview: Clinical Investigation
-
HCV protease inhibitors: using the evidence to guide clinical practice
Derek Yu, Jordan J Feld
Review: Clinical Trail Outcomes: Clinical Investigation
-
HCV protease inhibitors: using the evidence to guide clinical practice
Derek Yu, Jordan J Feld
Review: Clinical Trail Outcomes: Clinical Investigation
-
HCV protease inhibitors: using the evidence to guide clinical practice
Derek Yu, Jordan J Feld
Review: Clinical Trail Outcomes: Clinical Investigation
-
HCV protease inhibitors: using the evidence to guide clinical practice
Derek Yu, Jordan J Feld
Review: Clinical Trail Outcomes: Clinical Investigation
-
HCV protease inhibitors: using the evidence to guide clinical practice
Derek Yu, Jordan J Feld
Review: Clinical Trail Outcomes: Clinical Investigation
-
HCV protease inhibitors: using the evidence to guide clinical practice
Derek Yu, Jordan J Feld
Review: Clinical Trail Outcomes: Clinical Investigation
-
HCV protease inhibitors: using the evidence to guide clinical practice
Derek Yu, Jordan J Feld
Review: Clinical Trail Outcomes: Clinical Investigation
-
HCV protease inhibitors: using the evidence to guide clinical practice
Derek Yu, Jordan J Feld
Review: Clinical Trail Outcomes: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation